OOIR: Observatory of International Research

Papers

(The TQCC of Pharmacology & Therapeutics is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Editorial Board	462
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	434
Lipid metabolism in AKI and AKI-CKD transition: Dysregulation, lipotoxicity and therapeutic potential	379
Treatment strategies for leptomeningeal disease in patients with breast cancer	294
Unfolded protein responses: Dynamic machinery in wound healing	289
Editorial Board	252
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	222
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	216
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	209
Adenosine receptor signalling as a driver of pulmonary fibrosis	178
Matrikines in the skin: Origin, effects, and therapeutic potential	169
Treatment approaches for alcohol use disorder with metabolic dysfunction	130
The role of macrophages in asthma-related fibrosis and remodelling	128
Collateral lethality: A unique type of synthetic lethality in cancers	127
Retinoid dynamics in vision: from visual cycle biology to retina disease treatments	120
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	115
Inflammation, lipids, and pain in vulvar disease	113
Non-canonical G protein signaling	112
Endothelial dysfunction as a complication of anti-cancer therapy	99
SGLT2 inhibitors: Do they have antiarrhythmic properties?	95
Potential neonatal toxicity of new psychoactive substances	94
Editorial Board	93
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	93
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	90
TAAR1 as an emerging target for the treatment of psychiatric disorders	89

Management of drug-resistant hypertension as a heterogeneous disorder	89
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	87
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	86
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	84
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	83
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	81
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	81
Boron in cancer therapeutics: An overview	81
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	78
Dysregulation of metabolic pathways in pulmonary fibrosis	77
Review: Sex-related differences in the treatment of cardiac arrhythmia	77
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	77
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	75
Natural products that alleviate depression: The putative role of autophagy	75
Bispecific antibodies for the treatment of neuroblastoma	74
Editorial Board	73
Editorial Board	73
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	72
N6-methyladenosine (m6A) RNA methylation: a potential clinical therapeutic target in cardiocerebrovascular diseases	72
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	71
PGRMC1: An enigmatic heme-binding protein	70
Pharmacological treatment of cardiogenic shock – A state of the art review	70
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	68
A dive into the untapped potential of marine compounds in counteracting neurodegeneration	67
Stabilizing the neural barrier – A novel approach in pain therapy	66
Unravelling the complexity of cancer premetastatic niche - Mechanistic insights and clinical therapies	66
Air pollution and diseases: signaling, G protein-coupled and Toll like receptors	65
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	65
Insights into effective protocol structuring: optimizing dosing strategies, experimental design, and statistical approaches	65
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	63
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	63
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	63
Advances in pathogenesis and therapeutic strategies for osteoporosis	63
DNA methylation in cell plasticity and malignant transformation in liver diseases	63
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	61
HDL-based therapeutics: A promising frontier in combating viral and bacterial infections	60
Regulation of feeding and therapeutic application of bioactive peptides	57
Neuromuscular and cardiac organoids and assembloids: Advanced platforms for drug testing	57
Editorial: Beyond the opioid crisis: New targets for the management of chronic pain	56
The role of drug-metabolizing enzymes in synthetic lethality of cancer	55
Optimizing drug therapies in cardiac amyloidosis	55
Noncoding RNA circuitry in melanoma onset, plasticity, and therapeutic response	55
Drug-induced Torsades de pointes: Insights from a canine model of chronic atrioventricular block	54
Myeloperoxidase: Growing importance in cancer pathogenesis and potential drug target	53
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease	53
MAS-related G protein-coupled receptors X (MRGPRX): Orphan GPCRs with potential as targets for future drugs	53
Therapeutic targeting of DNA methylation alterations in cancer	53
Emerging roles of RNA ac4C modification and NAT10 in mammalian development and human diseases	53

Editorial Board	52
Pathological changes in GPCR signal organisation: Opportunities for targeted therapies for triple negative breast cancer	52
Chemical diversity, traditional uses, and bioactivities of Rosa roxburghii Tratt: A comprehensive review	52
Corrigendum to “Drug discovery through biophysical techniques: Methods and applications” [pharmacology and therapeutics volume 277 (2026) 108947]	52
Update on treatment of abdominal pain in irritable bowel syndrome: A narrative review	51
Pharmacological potential of cyclic nucleotide signaling in immunity	51
Cerebrovascular protective functions of amyloid precursor protein: Progress and therapeutic prospects	51
Editorial Board	51
Bridging the gap: The endocannabinoid system as a functional fulcrum for benzodiazepines in a novel frontier of anxiety pharmacotherapy	51
Therapeutic exploration of biased ligands at class A G protein-coupled receptors over the past 20 years	50
Immunotherapy for hepatocellular carcinoma: Recent advances and future targets	50
Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation	50
The emerging science of Glioception: Contribution of glia in sensing, transduction, circuit integration of interoception	50
Cannabinoid receptor 1 ligands: Biased signaling mechanisms driving functionally selective drug discovery	49
CDNF and ER stress: Pharmacology and therapeutic possibilities	49
Organic anion transporters in remote sensing and organ crosstalk	48
Integrins in cancer: Emerging mechanisms and therapeutic opportunities	48
MicroRNAs in drug addiction: Current status and future perspectives	48
Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials	48
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment	48
Editorial Board	47
The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets	46
The role and participation of immune cells in the endometrial tumor microenvironment	46
The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease	46
Oxidative stress and antioxidant therapeutic mechanisms	45
Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions	45
Exploring the landscape of post-translational modification in drug discovery	45
Molecular mechanisms of ferroptosis and their involvement in brain diseases	45
G protein-coupled estrogen receptor biased signaling in health and disease	45
Neurobiological mechanisms of botulinum neurotoxin-induced analgesia for neuropathic pain	45
Pharmacological interventions for intraplaque neovascularization in atherosclerosis	45
Phosphorylation of nuclear receptors: Novelty and therapeutic implications	44
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation	44
Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects	44
Platelet lipid metabolism in vascular thrombo-inflammation	43
Attributes novel drug candidate: Constitutive GPCR signal bias mediated by purinergic receptors	43
Understanding the molecular bridges between the drugs and immune cell	43
Potential targeting of the tumor microenvironment to improve cancer virotherapy	43
Development and clinical translation of P2X7 receptor antagonists: A potential therapeutic target in coronary artery disease?	42
Annexin A1 in neurological disorders: Neuroprotection and glial modulation	41
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities	41
Mathematical modeling of T cell exhaustion in the tumor microenvironment	41
RNA renaissance: Harnessing non-coding RNA therapeutics for hepatocellular carcinoma	41
Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations	40
Prolactin and pain of endometriosis	40
Editorial Board	40
Targeting cell cycle checkpoints for glioma therapy	40
Post-COVID pulmonary sequelae: Mechanisms and potential targets to reduce persistent fibrosis	40
Plant-derived nanovesicles and therapeutic application	39
The essential role of docosahexaenoic acid and its derivatives for retinal integrity	39
Roles of NLRC4 inflammasome in neurological disorders: Mechanisms, implications, and therapeutic potential	39
Early life adversities, psychopathologies and novel pharmacological strategies	39
Modulating glucocorticoid receptor actions in physiology and pathology: Insights from coregulators	39
From bench to clinic: Emerging therapies for corneal scarring	38
Signaling pathways in brain ischemia: Mechanisms and therapeutic implications	38
Editorial Board	37
Targeting the Semaphorin3E-plexinD1 complex in allergic asthma	37
Gene and stem cell therapy for inherited cardiac arrhythmias	37
Immune cells and their derived microRNA-enriched extracellular vesicles in nonalcoholic fatty liver diseases: Novel therapeutic targets	37
Editorial Board	37
The antidepressant actions of ketamine and its enantiomers	37
Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease	36
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections	36
Retina-directed gene therapy: Achievements and remaining challenges	36
GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?	36
Biased signaling in drug discovery and precision medicine	35
Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis	35
Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics	35
Anti-cancer activity of sustained release capsaicin formulations	35
Bile acids and neurological disease	35
Endotheliopathy in the metabolic syndrome: Mechanisms and clinical implications	35
Chloride channels in the lung: Challenges and perspectives for viral infections, pulmonary arterial hypertension, and cystic fibrosis	35